
Tanja D. De Gruijl
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 237 publications
Author Correction: The evolving role of cytokines for CAR-T cell manufacturing and beyond.
Journal: Nature biomedical engineering
Published: August 10, 2026
Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.
Journal: Journal for immunotherapy of cancer
Published: June 11, 2026
Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.
Journal: Journal for immunotherapy of cancer
Published: June 03, 2026
Local immunotherapy for the treatment of cancer: scientific advances and clinical potential.
Journal: Journal for immunotherapy of cancer
Published: April 20, 2026
The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 17, 2026
Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?
Journal: Journal for immunotherapy of cancer
Published: March 16, 2026
Reducing sialylation in melanoma increases classical pathway-mediated complement activation.
Journal: iScience
Published: March 06, 2026
A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies.
Journal: Clinical immunology (Orlando, Fla.)
Published: December 29, 2025
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC.
Journal: Journal for immunotherapy of cancer
Published: November 03, 2025
Voices: Future directions in targeting the tumor microenvironment.
Journal: Cell reports. Medicine
Published: October 17, 2025
PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment.
Journal: Journal for immunotherapy of cancer
Published: October 08, 2025
Last Updated: 09/26/2026